Lorenza Rimassa
@lorenzarimassa.bsky.social
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma
Reposted by Lorenza Rimassa
I wrote this song on Saturday, recorded it yesterday and released it to you today in response to the state terror being visited on the city of Minneapolis. It’s dedicated to the people of Minneapolis, our innocent immigrant neighbors and in memory of Alex Pretti and Renee Good.
Stay free
Stay free
Bruce Springsteen - Streets Of Minneapolis (Official Audio)
YouTube video by Bruce Springsteen
youtu.be
January 28, 2026 at 5:02 PM
I wrote this song on Saturday, recorded it yesterday and released it to you today in response to the state terror being visited on the city of Minneapolis. It’s dedicated to the people of Minneapolis, our innocent immigrant neighbors and in memory of Alex Pretti and Renee Good.
Stay free
Stay free
@acammarota.bsky.social presenting her work on clinical predictors and molecular architecture of #TLS in #CCA 🔬at @easlnews.bsky.social #LiverCancerSummit in Edinburgh.
Great job! 👏🏻👏🏻👏🏻
#AnaLleo #HumanitasUniversity #Humanitas
Great job! 👏🏻👏🏻👏🏻
#AnaLleo #HumanitasUniversity #Humanitas
January 24, 2026 at 9:49 PM
@acammarota.bsky.social presenting her work on clinical predictors and molecular architecture of #TLS in #CCA 🔬at @easlnews.bsky.social #LiverCancerSummit in Edinburgh.
Great job! 👏🏻👏🏻👏🏻
#AnaLleo #HumanitasUniversity #Humanitas
Great job! 👏🏻👏🏻👏🏻
#AnaLleo #HumanitasUniversity #Humanitas
Reposted by Lorenza Rimassa
We’re in for an engaging hour with an international & multidisciplinary hepatobiliary tumor board tackling complex HCC cases during the #GI26 “Liver Power Hour” chaired by Dr. Riad Salem & Dr. Nina Niu Sanford. #hpbcsm
meetings.asco.org/meetings/202...
@lorenzarimassa.bsky.social
meetings.asco.org/meetings/202...
@lorenzarimassa.bsky.social
January 9, 2026 at 10:59 PM
We’re in for an engaging hour with an international & multidisciplinary hepatobiliary tumor board tackling complex HCC cases during the #GI26 “Liver Power Hour” chaired by Dr. Riad Salem & Dr. Nina Niu Sanford. #hpbcsm
meetings.asco.org/meetings/202...
@lorenzarimassa.bsky.social
meetings.asco.org/meetings/202...
@lorenzarimassa.bsky.social
Early morning start at @ascocancer.bsky.social #GI26 in San Francisco. Excited to meet friends and colleagues and discuss treatment options for patients with #HCC #CCA #BTC #PDAC #HumanitasUniversity #Humanitas
January 9, 2026 at 10:09 PM
Early morning start at @ascocancer.bsky.social #GI26 in San Francisco. Excited to meet friends and colleagues and discuss treatment options for patients with #HCC #CCA #BTC #PDAC #HumanitasUniversity #Humanitas
Traveling to Singapore for #ESMOAsia25. Looking forward to meeting with friends and colleagues and discussing new therapeutic options for patients with #GI cancers #HCC #CCA #BTC @myesmo.bsky.social
December 3, 2025 at 7:39 AM
Traveling to Singapore for #ESMOAsia25. Looking forward to meeting with friends and colleagues and discussing new therapeutic options for patients with #GI cancers #HCC #CCA #BTC @myesmo.bsky.social
Please have a look at our editorial published in #ASCODailyNews
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma
The treatment landscape for unresectable hepatocellular carcinoma has undergone profound change over the past 5 years, presenting both unprecedented opportunities and complex decision-making challenge...
dailynews.ascopubs.org
November 14, 2025 at 3:19 PM
Please have a look at our editorial published in #ASCODailyNews
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...
Reposted by Lorenza Rimassa
🤖 How can generative and foundation models reshape oncology, - from research to clinical practice?
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
October 25, 2025 at 6:17 AM
🤖 How can generative and foundation models reshape oncology, - from research to clinical practice?
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
Find out in the session “Generative AI” at #ESMOAI25 in Berlin.
👉 www.esmo.org/meeting-cale...
JulieHeimbach discusses #livertransplant for patients with intrahepatic or perihilar #cholangiocarcinoma #CCA at the Advances in Hepatology Symposium in Berlin #FalkFoundation
October 25, 2025 at 10:03 AM
JulieHeimbach discusses #livertransplant for patients with intrahepatic or perihilar #cholangiocarcinoma #CCA at the Advances in Hepatology Symposium in Berlin #FalkFoundation
Reposted by Lorenza Rimassa
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
October 19, 2025 at 1:49 PM
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
October 20, 2025 at 9:53 AM
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
#ESMO25
#myESMOStory
#ESMOAmbassadors
October 20, 2025 at 9:45 AM
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
#ESMO25
#myESMOStory
#ESMOAmbassadors
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:49 AM
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Reposted by Lorenza Rimassa
🎉 Your #myESMOStory moments made ESMO’s 50th anniversary special.
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
October 20, 2025 at 7:43 AM
🎉 Your #myESMOStory moments made ESMO’s 50th anniversary special.
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
From selfies at #ESMO25 to memories shared from afar, together we marked 50 years of progress in oncology.
Here’s to accelerating impact! #ONEoncologycommunity
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:44 AM
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:34 AM
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:26 AM
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:18 AM
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:13 AM
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:56 AM
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:49 AM
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:41 AM
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Interested in or worried about #LargeLanguageModels in #ClinicalPractice? The @myesmo.bsky.social Guidance (#ELCAP) is out and ready for download!
#ESMO25 #ESMOAmbassadors
#ESMO25 #ESMOAmbassadors
The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively.
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
October 19, 2025 at 12:35 PM
Interested in or worried about #LargeLanguageModels in #ClinicalPractice? The @myesmo.bsky.social Guidance (#ELCAP) is out and ready for download!
#ESMO25 #ESMOAmbassadors
#ESMO25 #ESMOAmbassadors
Reposted by Lorenza Rimassa
The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively.
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
October 19, 2025 at 7:45 AM
The ESMO Guidance on the use of #LargeLanguageModels in #ClinicalPractice (#ELCAP) is out: the first structured set of recommendations to bring #AI language models into #oncology safely and effectively.
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
#ESMOAI25 #ESMO25 #LLMs #HealthAI
🔗 buff.ly/pg1gkiU
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 9:40 AM
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social